Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

Spyre Therapeutics, Inc.

SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.
No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.
Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.
Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.
Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.